2015-08-06, BAHADORİ, FATEMEH, ÇELİK, BURAK, Kazdal, Fatma, KUŞMAN, TUBA, BAHADORİ, FATEMEH, ÇELİK, BURAK, KUŞMAN, TUBA

2017-01-01, Celik, BURAK, Ozdemir, Samet, Demirkoz, Asli Barla, Uner, Melike, ÇELİK, BURAK

Objective: The aim of this study was optimization of buccal piribedil (PR) mucoadhesive tablets to improve its low bioavailability and provide controlled release for the treatment of Parkinson-s disease.

2017-10-04, ASRAM SAĞIROĞLU, ALİ, ÇELİK, BURAK, ÖZDEMIR, S, ASRAM SAĞIROĞLU, ALİ, ÇELİK, BURAK

2015-11-28, ÇELİK, BURAK, ÜNER, M, ÇELİK, BURAK

2017-09-01, ÖNYÜKSEL, Hayat, BAHADORİ, FATEMEH, ÇELİK, BURAK, BAHADORİ, FATEMEH, ÇELİK, BURAK

2018-06-01T00:00:00Z, Ozdemir, Samet, Celik, BURAK, Sumer, Engin, Acar, Ebru Turkoz, Uner, Melike, ÇELİK, BURAK

The aim of the present complimentary study was to investigate physical stability of eplerenone (EP) loaded nanoemulsions and to evaluate their pharmacokinetic profiles after subcutaneous application to Sprague Dawley rats. Nanoemulsions were prepared by using high shear homogenization and ultrasonication techniques. All formulations were having 0.1% EP. They were obtained in 150.6 nm-205.8 nm size range. Physical stability of nanoemulsions was monitored storing them at different thermal conditions for 120 days. Droplet size was confirmed to be affected by storage temperature when it slightly changed at 4 +/- 2 degrees C and 25 +/- 2 degrees C. 40 +/- 2 degrees C was found not to be suitable as a storage condition in general. Pharmacokinetic study on physically stable formulations demonstrated that subcutaneously applied eplerenone solution showed that AUC(0)->infinity and C-max were 1.62 and 2.05 folds higher than eplerenone solution after oral administration. Additionally, AUC(0)->infinity and C-max were significantly increased in the case of nanoemulsions prepared with Brij (R) 35 and Tween (R) 80. Relative bioavailability of the drug was found to be remarkably increased after administration of formulations stabilized with Tween (R) 80. Results suggested that eplerenone loaded nanoemulsions may provide an alternative application way for efficient management of hypertension attacks.

2016-12-01, Elbay, AHMET, CELIK, U, CELIK, BURAK, OZER, OF, KILIC, GÖKHAN, AKKAN, JC, BAYRAKTAR, BİLGE, KAYMAK, NZ, ELBAY, AHMET, ÇELİK, BURAK, ÖZER, ÖMER FARUK, KILIC, GÖKHAN, BAYRAKTAR, BILGE

2017-01-01, Uner, Melike, Damgali, Sukran, Ozdemir, Samet, Celik, BURAK, ÇELİK, BURAK

Background: Solid lipid nanoparticles (SLN) are colloidal drug carrier systems that contribute several properties required from a sophisticated drug delivery system for increasing drug bioavailability and providing effective therapy. Many advantages of SLN have been reported over traditional dosage forms and their colloidal counterparts since the early 1990s. They were optimized for oral drug delivery for the first time. The first SLN formulations were produced by reducing particle size of solid lipid microparticles by spray congealing technique in the late 1980s. Then, studies have been continued investigating for their different administration routes else including parenteral, transdermal, ocular, nasal, respiratory etc.

2015-08-06, Kazdal, Fatma, ÇELİK, BURAK, BAHADORİ, FATEMEH, Ertaş, Abdulselam, ÇELİK, BURAK, BAHADORİ, FATEMEH

2015-06-12, BAHADORİ, FATEMEH, Kazdal, Fatma, ÇELİK, BURAK, BAHADORİ, FATEMEH, ÇELİK, BURAK